

Hospital Acquired Infections Therapeutic Market Size, Share & Trends Analysis Report By Drug Class (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs), By Infection Type, By Region, And Segment Forecasts, 2020 - 2027

<https://marketpublishers.com/r/HD1A623FBA68EN.html>

Date: February 2021

Pages: 120

Price: US\$ 5,950.00 (Single User License)

ID: HD1A623FBA68EN

Abstracts

This report can be delivered to the clients within 72 Business Hours

Hospital Acquired Infections Therapeutic Market Growth & Trends

The global hospital acquired infections therapeutic market size is expected to reach USD 12.5 billion by 2027, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 2.4% from 2020 to 2027. The high prevalence of HAIs, rise in approval and launch of new drugs, and growing hospitalization due to the rise in prevalence of chronic diseases are driving the market.

According to the data published by the New York State Department of Health in November 2019, around 160 hospitals in New York reported total cases of around 1,139 colon SSIs out of 19,732 procedures in 2018, a rate of 5.8 infections per 100 procedures. The same source also states that in 2018, around 15,310 cases of *Clostridioides difficile* infections (CDI) were reported in acute care hospitals located in New York. Such, high prevalence of hospital-acquired infections is anticipated to significantly raise the demand for its treatment therapies and support the HAIs therapeutics market growth over the forecast period.

Furthermore, key players in the market are involved in extensive R&D initiatives for the development and indication expansion of its already approved drugs for HAI treatment. For instance, in February 2018, the FDA approved Allergan plc's supplemental New

Drug Application (sNDA) and expanded the approval of Avycaz (ceftazidime and avibactam) to include the treatment of HABP/VABP and hospital-acquired bacterial pneumonia.

Hospital Acquired Infections Therapeutic Market Report Highlights

Antibacterial drugs dominated the drug class segment in 2019, owing to the high adoption of antibiotics as the first line of treatment for hospital-acquired infections (HAIs)

The surgical site infections (SSIs) segment held the largest market share in 2019 due to the rising number of surgical procedures and subsequent rising cases of SSIs

The urinary tract infections (UTIs) segment is anticipated to show the fastest growth rate during the forecast period owing to the growing number of UTI cases and rising awareness among people about the disease condition in less-developed countries

The introduction of novel drugs by key players, for instance, Merck to treat ventilator-associated pneumonia has led to a high growth of the market

The high prevalence of HAIs in the European countries is the major factor significantly driving the demand for its medications in this region

Growing awareness levels about various risk factors associated with HAIs in ICU and other emergency care settings is expected to propel market growth in the Asia Pacific region

Contents

CHAPTER 1 METHODOLOGY AND SCOPE

- 1.1 Market segmentation & scope
- 1.2 Market definition
- 1.3 Information procurement
 - 1.3.1 Purchased database
 - 1.3.2 GVR's internal database
 - 1.3.3 Secondary sources & third party perspectives
 - 1.3.4 Primary research
- 1.4 Information analysis
 - 1.4.1 Data analysis models
- 1.5 Market formulation & data visualization
- 1.6 Data validation & publishing

CHAPTER 2 EXECUTIVE SUMMARY

- 2.1 Market Outlook
- 2.2 Segment Outlook
- 2.3 Competitive Insights

CHAPTER 3 HOSPITAL-ACQUIRED INFECTIONS (HAI) THERAPEUTICS MARKET VARIABLES, TRENDS & SCOPE

- 3.1 Market Lineage Outlook
 - 3.1.1 Parent Market Outlook
 - 3.1.2 Ancillary Market Outlook
- 3.2 Penetration and Growth Prospect Mapping
- 3.3 Market Dynamics
 - 3.3.1 Market driver analysis
 - 3.3.1.1 Rise in approval and launch of new drugs
 - 3.3.1.2 Increasing hospitalization due to rising burden of chronic diseases
 - 3.3.1.3 High prevalence of HAIs
 - 3.3.2 Market Restraint Analysis
 - 3.3.2.1 Declining demand for HAI drugs
 - 3.3.3 Industry challenges
- 3.4 Hospital-acquired Infections (HAI) Therapeutics Market Analysis Tools
 - 3.4.1 Industry analysis - Porter's

- 3.4.1.1 Supplier Power
- 3.4.1.2 Buyer Power
- 3.4.1.3 Substitution Threat
- 3.4.1.4 Threat from new entrants
- 3.4.1.5 Competitive Rivalry
- 3.4.2 PESTEL Analysis
 - 3.4.2.1 Political Landscape
 - 3.4.2.2 Environmental Landscape
 - 3.4.2.3 Social landscape
 - 3.4.2.4 Technology landscape
 - 3.4.2.5 Legal Landscape
- 3.4.3 Major deals and strategic alliances analysis
 - 3.4.3.1 Joint ventures
 - 3.4.3.2 Mergers and acquisitions
 - 3.4.3.3 Licensing and partnership
 - 3.4.3.4 Technology collaborations
 - 3.4.3.5 Strategic Divestments
- 3.4.4 Market entry strategies

CHAPTER 4 HOSPITAL-ACQUIRED INFECTIONS (HAI) THERAPEUTICS MARKET - COMPETITIVE ANALYSIS

- 4.1 Recent Developments & Impact Analysis, by Key Market Participants
- 4.2 Vendor Landscape
 - 4.2.1 List of key distributors and channel partners
 - 4.2.2 Key company market share analysis, 2019
- 4.3 Public Companies
 - 4.3.1 Company market position analysis
 - 4.3.2 Competitive dashboard analysis
- 4.4 Private Companies
 - 4.4.1 List of key emerging companies
 - 4.4.2 Regional network map
 - 4.4.3 Company market position analysis

CHAPTER 5 HOSPITAL-ACQUIRED INFECTIONS (HAI) THERAPEUTICS MARKET: DRUG CLASS ESTIMATES AND TREND ANALYSIS

- 5.1 Definition & Scope
- 5.2 Drug Class Market Share Analysis, 2019 & 2027

5.3 Segment Dashboard

5.4 Global Hospital-acquired Infections (HAI) Therapeutics Market, by Drug Class, 2016 to 2027

5.5 Market Size & Forecasts and Trend Analyses, 2016 to 2027

5.5.1 Antibacterial Drugs

5.5.1.1 Antibacterial Drugs Market Estimates and Forecasts, 2016 to 2027 (USD Million)

5.5.1.2 Cell Wall Synthesis Inhibitors

5.5.1.2.1 Cell Wall Synthesis Inhibitors Market Estimates and Forecasts, 2016 to 2027 (USD Million)

5.5.1.3 Protein Synthesis Inhibitors

5.5.1.3.1 Protein Synthesis Inhibitors Market Estimates and Forecasts, 2016 to 2027 (USD Million)

5.5.1.4 Others

5.5.1.4.1 Others Market Estimates and Forecasts, 2016 to 2027 (USD Million)

5.5.2 Antiviral Drugs

5.5.2.1 Antiviral Drugs Market Estimates and Forecasts, 2016 to 2027 (USD Million)

5.5.3 Antifungal Drugs

5.5.3.1 Antifungal Drugs Market Estimates and Forecasts, 2016 to 2027 (USD Million)

CHAPTER 6 HOSPITAL-ACQUIRED INFECTIONS (HAI) THERAPEUTICS MARKET: INFECTION TYPE ESTIMATES AND TREND ANALYSIS

6.1 Definition & Scope

6.2 Infection Type Market Share Analysis, 2019 & 2027

6.3 Segment Dashboard

6.4 Global Hospital-acquired Infections (HAI) Therapeutics Market, by Infection Type, 2016 to 2027

6.5 Market Size & Forecasts and Trend Analyses, 2016 to 2027

6.5.1 Urinary Tract Infections

6.5.1.1 Urinary Tract Infections Market Estimates and Forecasts, 2016 to 2027 (USD Million)

6.5.2 Ventilator Associated Pneumonia

6.5.2.1 Ventilator Associated Pneumonia Market Estimates and Forecasts, 2016 to 2027 (USD Million)

6.5.3 Surgical Site Infections

6.5.3.1 Surgical Site Infections Market Estimates and Forecasts, 2016 to 2027 (USD Million)

6.5.4 Bloodstream Infections

6.5.4.1 Bloodstream Infections Market Estimates and Forecasts, 2016 to 2027 (USD Million)

6.5.5 Others

6.5.5.1 Others Market Estimates and Forecasts, 2016 to 2027 (USD Million)

CHAPTER 7 HOSPITAL-ACQUIRED INFECTIONS (HAI) THERAPEUTICS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS

7.1 Regional Market Snapshot

7.2 Regional Market Share and Leading Players, 2019

7.2.1 North America

7.2.2 Europe

7.2.3 Asia Pacific

7.2.4 Latin America

7.2.5 Middle East & Africa

7.3 Market Share Analysis by Country, 2019

7.3.1 North America

7.3.1.1 U.S.

7.3.1.2 Canada

7.3.2 Europe

7.3.2.1 U.K.

7.3.2.2 Germany

7.3.2.3 Spain

7.3.2.4 France

7.3.2.5 Italy

7.3.2.6 Russia

7.3.3 Asia Pacific

7.3.3.1 Japan

7.3.3.2 China

7.3.3.3 India

7.3.3.4 South Korea

7.3.3.5 Singapore

7.3.3.6 Australia

7.3.4 Latin America

7.3.4.1 Brazil

7.3.4.2 Mexico

7.3.4.3 Argentina

7.3.5 Middle East & Africa

7.3.5.1 South Africa

7.3.5.2 Saudi Arabia

7.3.5.3 UAE

7.4 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

7.4.1 North America

7.4.2 Europe

7.4.3 Asia Pacific

7.4.4 Latin America

7.4.5 Middle East & Africa

7.5 Market Size & Forecasts, and Trend Analysis, 2019 to 2027

7.5.1 North America

7.5.1.1 North America Market Size & Forecasts and Trend Analysis, 2016 to 2027
(USD Million)

7.5.1.2 U.S.

7.5.1.2.1 U.S. Market Size & Forecasts and Trend Analysis, By Drug Class, 2016 to 2027 (USD million)

7.5.1.2.2 U.S. Market Size & Forecasts and Trend Analysis, By Infection Type, 2016 to 2027 (USD million)

7.5.1.3 Canada

7.5.1.3.1 Canada Market Size & Forecasts and Trend Analysis, By Drug Class, 2016 to 2027 (USD million)

7.5.1.3.2 Canada Market Size & Forecasts and Trend Analysis, By Infection Type, 2016 to 2027 (USD million)

7.5.2 Europe

7.5.2.1 Europe Market Size & Forecasts and Trend Analysis, 2016 to 2027 (USD Million)

7.5.2.2 U.K.

7.5.2.2.1 U.K. Market Size & Forecasts and Trend Analysis, By Drug Class, 2016 to 2027 (USD million)

7.5.2.2.2 U.K. Market Size & Forecasts and Trend Analysis, By Infection Type, 2016 to 2027 (USD million)

7.5.2.3 Germany

7.5.2.3.1 Germany Market Size & Forecasts and Trend Analysis, By Drug Class, 2016 to 2027 (USD million)

7.5.2.3.2 Germany Market Size & Forecasts and Trend Analysis, By Infection Type, 2016 to 2027 (USD million)

7.5.2.4 Spain

7.5.2.4.1 Spain Market Size & Forecasts and Trend Analysis, By Drug Class, 2016 to 2027 (USD million)

7.5.2.4.2 Spain Market Size & Forecasts and Trend Analysis, By Infection Type, 2016 to 2027 (USD million)

7.5.2.5 France

7.5.2.5.1 France Market Size & Forecasts and Trend Analysis, By Drug Class, 2016 to 2027 (USD million)

7.5.2.5.2 France Market Size & Forecasts and Trend Analysis, By Infection Type, 2016 to 2027 (USD million)

7.5.2.6 Italy

7.5.2.6.1 Italy Market Size & Forecasts and Trend Analysis, By Drug Class, 2016 to 2027 (USD million)

7.5.2.6.2 Italy Market Size & Forecasts and Trend Analysis, By Infection Type, 2016 to 2027 (USD million)

7.5.2.7 Russia

7.5.2.7.1 Russia Market Size & Forecasts and Trend Analysis, By Drug Class, 2016 to 2027 (USD million)

7.5.2.7.2 Russia Market Size & Forecasts and Trend Analysis, By Infection Type, 2016 to 2027 (USD million)

7.5.3 Asia Pacific

7.5.3.1 Asia Pacific Market Size & Forecasts and Trend Analysis, 2016 to 2027 (USD Million)

7.5.3.2 Japan

7.5.3.2.1 Japan Market Size & Forecasts and Trend Analysis, By Drug Class, 2016 to 2027 (USD million)

7.5.3.2.2 Japan Market Size & Forecasts and Trend Analysis, By Infection Type, 2016 to 2027 (USD million)

7.5.3.3 China

7.5.3.3.1 China Market Size & Forecasts and Trend Analysis, By Drug Class, 2016 to 2027 (USD million)

7.5.3.3.2 China Market Size & Forecasts and Trend Analysis, By Infection Type, 2016 to 2027 (USD million)

7.5.3.4 India

7.5.3.4.1 India Market Size & Forecasts and Trend Analysis, By Drug Class, 2016 to 2027 (USD million)

7.5.3.4.2 India Market Size & Forecasts and Trend Analysis, By Infection Type, 2016 to 2027 (USD million)

7.5.3.5 South Korea

7.5.3.5.1 South Korea Market Size & Forecasts and Trend Analysis, By Drug Class, 2016 to 2027 (USD million)

7.5.3.5.2 South Korea Market Size & Forecasts and Trend Analysis, By Infection

Type, 2016 to 2027 (USD million)

7.5.3.6 Singapore

7.5.3.6.1 Singapore Market Size & Forecasts and Trend Analysis, By Drug Class, 2016 to 2027 (USD million)

7.5.3.6.2 Singapore Market Size & Forecasts and Trend Analysis, By Infection Type, 2016 to 2027 (USD million)

7.5.3.7 Australia

7.5.3.7.1 Australia Market Size & Forecasts and Trend Analysis, By Drug Class, 2016 to 2027 (USD million)

7.5.3.7.2 Australia Market Size & Forecasts and Trend Analysis, By Infection Type, 2016 to 2027 (USD million)

7.5.4 Latin America

7.5.4.1 Latin America Market Size & Forecasts and Trend Analysis, 2016 to 2027 (USD Million)

7.5.4.2 Brazil

7.5.4.2.1 Brazil Market Size & Forecasts and Trend Analysis, By Drug Class, 2016 to 2027 (USD million)

7.5.4.2.2 Brazil Market Size & Forecasts and Trend Analysis, By Infection Type, 2016 to 2027 (USD million)

7.5.4.3 Mexico

7.5.4.3.1 Mexico Market Size & Forecasts and Trend Analysis, By Drug Class, 2016 to 2027 (USD million)

7.5.4.3.2 Mexico Market Size & Forecasts and Trend Analysis, By Infection Type, 2016 to 2027 (USD million)

7.5.4.4 Argentina

7.5.4.4.1 Argentina Market Size & Forecasts and Trend Analysis, By Drug Class, 2016 to 2027 (USD million)

7.5.4.4.2 Argentina Market Size & Forecasts and Trend Analysis, By Infection Type, 2016 to 2027 (USD million)

7.5.5 Middle East & Africa

7.5.5.1 Middle East & Africa Market Size & Forecasts and Trend Analysis, 2016 to 2027 (USD Million)

7.5.5.2 South Africa

7.5.5.2.1 South Africa Market Size & Forecasts and Trend Analysis, By Drug Class, 2016 to 2027 (USD million)

7.5.5.2.2 South Africa Market Size & Forecasts and Trend Analysis, By Infection Type, 2016 to 2027 (USD million)

7.5.5.3 Saudi Arabia

7.5.5.3.1 Saudi Arabia Market Size & Forecasts and Trend Analysis, By Drug Class,

2016 to 2027 (USD million)

7.5.5.3.2 Saudi Arabia Market Size & Forecasts and Trend Analysis, By Infection Type, 2016 to 2027 (USD million)

7.5.5.4 UAE

7.5.5.4.1 UAE Market Size & Forecasts and Trend Analysis, By Drug Class, 2016 to 2027 (USD million)

7.5.5.4.2 UAE Market Size & Forecasts and Trend Analysis, By Infection Type, 2016 to 2027 (USD million)

CHAPTER 8 COMPANY PROFILE

8.1 Company Profiles

8.1.1 MERCK & CO., Inc.

8.1.1.1 Company overview

8.1.1.2 Financial Performance

8.1.1.3 Product benchmarking

8.1.1.4 Strategic initiatives

8.1.2 Pfizer Inc.

8.1.2.1 Company overview

8.1.2.2 Financial Performance

8.1.2.3 Product benchmarking

8.1.2.4 Strategic initiatives

8.1.3 Bayer AG

8.1.3.1 Company overview

8.1.3.2 Financial Performance

8.1.3.3 Product benchmarking

8.1.3.4 Strategic initiatives

8.1.4 GlaxoSmithKline

8.1.4.1 Company overview

8.1.4.2 Financial Performance

8.1.4.3 Product benchmarking

8.1.4.4 Strategic initiatives

8.1.5 Daiichi Sankyo Company, Limited

8.1.5.1 Company overview

8.1.5.2 Financial Performance

8.1.5.3 Product benchmarking

8.1.5.4 Strategic initiatives

8.1.6 AbbVie Inc.

8.1.6.1 Company overview

- 8.1.6.2 Financial Performance
- 8.1.6.3 Product benchmarking
- 8.1.6.4 Strategic initiatives
- 8.1.7 Basilea Pharmaceutica AG
 - 8.1.7.1 Company overview
 - 8.1.7.2 Financial Performance
 - 8.1.7.3 Product benchmarking
 - 8.1.7.4 Strategic initiatives
- 8.1.8 Abbott
 - 8.1.8.1 Company overview
 - 8.1.8.2 Financial Performance
 - 8.1.8.3 Product benchmarking
 - 8.1.8.4 Strategic initiatives
- 8.1.9 F. Hoffmann-La Roche Ltd
 - 8.1.9.1 Company overview
 - 8.1.9.2 Financial Performance
 - 8.1.9.3 Product benchmarking
 - 8.1.9.4 Strategic initiatives
- 8.1.10 Allergan Plc.
 - 8.1.10.1 Company overview
 - 8.1.10.2 Financial Performance
 - 8.1.10.3 Product benchmarking
 - 8.1.10.4 Strategic initiatives

List Of Tables

LIST OF TABLES

Table 1 List of key distributors and channel partners

Table 2 List of key emerging companies'/technology disruptors/innovators

Table 3 North America hospital-acquired infections therapeutics market, by countries, 2016 - 2027 (USD Million)

Table 4 North America hospital-acquired infections therapeutics market, by drug class, 2016 - 2027 (USD Million)

Table 5 North America hospital-acquired infections therapeutics market, by antibacterial drugs, 2016 - 2027 (USD Million)

Table 6 North America hospital-acquired infections therapeutics market, by infection type, 2016 - 2027 (USD Million)

Table 7 U.S. hospital-acquired infections therapeutics market, by drug class, 2016 - 2027 (USD Million)

Table 8 U.S. hospital-acquired infections therapeutics market, by antibacterial drugs, 2016 - 2027 (USD Million)

Table 9 U.S. hospital-acquired infections therapeutics market, by infection type, 2016 - 2027 (USD Million)

Table 10 Canada hospital-acquired infections therapeutics market, by drug class, 2016 - 2027 (USD Million)

Table 11 Canada hospital-acquired infections therapeutics market, by antibacterial drugs, 2016 - 2027 (USD Million)

Table 12 Canada hospital-acquired infections therapeutics market, by infection type, 2016 - 2027 (USD Million)

Table 13 Europe hospital-acquired infections therapeutics market, by countries, 2016 - 2027 (USD Million)

Table 14 Europe hospital-acquired infections therapeutics market, by drug class, 2016 - 2027 (USD Million)

Table 15 Europe hospital-acquired infections therapeutics market, by antibacterial drugs, 2016 - 2027 (USD Million)

Table 16 Europe hospital-acquired infections therapeutics market, by infection type, 2016 - 2027 (USD Million)

Table 17 Germany hospital-acquired infections therapeutics market, by drug class, 2016 - 2027 (USD Million)

Table 18 Germany hospital-acquired infections therapeutics market, by antibacterial drugs, 2016 - 2027 (USD Million)

Table 19 Germany hospital-acquired infections therapeutics market, by infection type,

2016 - 2027 (USD Million)

Table 20 U.K. hospital-acquired infections therapeutics market, by drug class, 2016 - 2027 (USD Million)

Table 21 U.K. hospital-acquired infections therapeutics market, by antibacterial drugs, 2016 - 2027 (USD Million)

Table 22 U.K. hospital-acquired infections therapeutics market, by infection type, 2016 - 2027 (USD Million)

Table 23 France hospital-acquired infections therapeutics market, by drug class, 2016 - 2027 (USD Million)

Table 24 France hospital-acquired infections therapeutics market, by antibacterial drugs, 2016 - 2027 (USD Million)

Table 25 France hospital-acquired infections therapeutics market, by infection type, 2016 - 2027 (USD Million)

Table 26 Italy hospital-acquired infections therapeutics market, by drug class, 2016 - 2027 (USD Million)

Table 27 Italy hospital-acquired infections therapeutics market, by antibacterial drugs, 2016 - 2027 (USD Million)

Table 28 Italy hospital-acquired infections therapeutics market, by infection type, 2016 - 2027 (USD Million)

Table 29 Spain hospital-acquired infections therapeutics market, by drug class, 2016 - 2027 (USD Million)

Table 30 Spain hospital-acquired infections therapeutics market, by antibacterial drugs, 2016 - 2027 (USD Million)

Table 31 Spain hospital-acquired infections therapeutics market, by infection type, 2016 - 2027 (USD Million)

Table 32 Russia hospital-acquired infections therapeutics market, by drug class, 2016 - 2027 (USD Million)

Table 33 Russia hospital-acquired infections therapeutics market, by antibacterial drugs, 2016 - 2027 (USD Million)

Table 34 Russia hospital-acquired infections therapeutics market, by infection type, 2016 - 2027 (USD Million)

Table 35 Asia Pacific hospital-acquired infections therapeutics market, by countries, 2016 - 2027 (USD Million)

Table 36 Asia Pacific hospital-acquired infections therapeutics market, by drug class, 2016 - 2027 (USD Million)

Table 37 Asia Pacific hospital-acquired infections therapeutics market, by antibacterial drugs, 2016 - 2027 (USD Million)

Table 38 Asia Pacific hospital-acquired infections therapeutics market, by infection type, 2016 - 2027 (USD Million)

Table 39 Japan hospital-acquired infections therapeutics market, by drug class, 2016 - 2027 (USD Million)

Table 40 Japan hospital-acquired infections therapeutics market, by antibacterial drugs, 2016 - 2027 (USD Million)

Table 41 Japan hospital-acquired infections therapeutics market, by infection type, 2016 - 2027 (USD Million)

Table 42 China hospital-acquired infections therapeutics market, by drug class, 2016 - 2027 (USD Million)

Table 43 China hospital-acquired infections therapeutics market, by antibacterial drugs, 2016 - 2027 (USD Million)

Table 44 China hospital-acquired infections therapeutics market, by infection type, 2016 - 2027 (USD Million)

Table 45 India hospital-acquired infections therapeutics market, by drug class, 2016 - 2027 (USD Million)

Table 46 India hospital-acquired infections therapeutics market, by antibacterial drugs, 2016 - 2027 (USD Million)

Table 47 India hospital-acquired infections therapeutics market, by infection type, 2016 - 2027 (USD Million)

Table 48 Australia hospital-acquired infections therapeutics market, by drug class, 2016 - 2027 (USD Million)

Table 49 Australia hospital-acquired infections therapeutics market, by antibacterial drugs, 2016 - 2027 (USD Million)

Table 50 Australia hospital-acquired infections therapeutics market, by infection type, 2016 - 2027 (USD Million)

Table 51 South Korea hospital-acquired infections therapeutics market, by drug class, 2016 - 2027 (USD Million)

Table 52 South Korea hospital-acquired infections therapeutics market, by antibacterial drugs, 2016 - 2027 (USD Million)

Table 53 South Korea hospital-acquired infections therapeutics market, by infection type, 2016 - 2027 (USD Million)

Table 54 Singapore hospital-acquired infections therapeutics market, by drug class, 2016 - 2027 (USD Million)

Table 55 Singapore hospital-acquired infections therapeutics market, by antibacterial drugs, 2016 - 2027 (USD Million)

Table 56 Singapore hospital-acquired infections therapeutics market, by infection type, 2016 - 2027 (USD Million)

Table 57 Latin America hospital-acquired infections therapeutics market, by countries, 2016 - 2027 (USD Million)

Table 58 Latin America hospital-acquired infections therapeutics market, by drug class,

2016 - 2027 (USD Million)

Table 59 Latin America hospital-acquired infections therapeutics market, by antibacterial drugs, 2016 - 2027 (USD Million)

Table 60 Latin America hospital-acquired infections therapeutics market, by infection type, 2016 - 2027 (USD Million)

Table 61 Brazil hospital-acquired infections therapeutics market, by drug class, 2016 - 2027 (USD Million)

Table 62 Brazil hospital-acquired infections therapeutics market, by antibacterial drugs, 2016 - 2027 (USD Million)

Table 63 Brazil hospital-acquired infections therapeutics market, by infection type, 2016 - 2027 (USD Million)

Table 64 Mexico hospital-acquired infections therapeutics market, by drug class, 2016 - 2027 (USD Million)

Table 65 Mexico hospital-acquired infections therapeutics market, by antibacterial drugs, 2016 - 2027 (USD Million)

Table 66 Mexico hospital-acquired infections therapeutics market, by infection type, 2016 - 2027 (USD Million)

Table 67 Argentina hospital-acquired infections therapeutics market, by drug class, 2016 - 2027 (USD Million)

Table 68 Argentina hospital-acquired infections therapeutics market, by antibacterial drugs, 2016 - 2027 (USD Million)

Table 69 Argentina hospital-acquired infections therapeutics market, by infection type, 2016 - 2027 (USD Million)

Table 70 MEA hospital-acquired infections therapeutics market, by drug class, 2016 - 2027 (USD Million)

Table 71 MEA hospital-acquired infections therapeutics market, by antibacterial drugs, 2016 - 2027 (USD Million)

Table 72 MEA hospital-acquired infections therapeutics market, by infection type, 2016 - 2027 (USD Million)

Table 73 South Africa hospital-acquired infections therapeutics market, by drug class, 2016 - 2027 (USD Million)

Table 74 South Africa hospital-acquired infections therapeutics market, by antibacterial drugs, 2016 - 2027 (USD Million)

Table 75 South Africa hospital-acquired infections therapeutics market, by infection type, 2016 - 2027 (USD Million)

Table 76 Saudi Arabia hospital-acquired infections therapeutics market, by drug class, 2016 - 2027 (USD Million)

Table 77 Saudi Arabia hospital-acquired infections therapeutics market, by antibacterial drugs, 2016 - 2027 (USD Million)

Table 78 Saudi Arabia hospital-acquired infections therapeutics market, by infection type, 2016 - 2027 (USD Million)

Table 79 UAE hospital-acquired infections therapeutics market, by drug class, 2016 - 2027 (USD Million)

Table 80 UAE hospital-acquired infections therapeutics market, by antibacterial drugs, 2016 - 2027 (USD Million)

Table 81 UAE hospital-acquired infections therapeutics market, by infection type, 2016 - 2027 (USD Million)

List Of Figures

LIST OF FIGURES

- Fig. 1 Hospital-acquired infections therapeutics market segmentation
- Fig. 2 Market research process
- Fig. 3 Information procurement
- Fig. 4 Primary research pattern
- Fig. 5 Market research approaches
- Fig. 6 Value chain based sizing & forecasting
- Fig. 7 QFD modelling for market share assessment
- Fig. 8 Hospital-acquired infections therapeutics market snapshot (2019)
- Fig. 9 Hospital-acquired infections therapeutics market: Segment snapshot (2019)
- Fig. 10 Competitive Insights (2019)
- Fig. 11 Parent market outlook
- Fig. 12 Related/ancillary market outlook
- Fig. 13 Penetration and growth prospect mapping
- Fig. 14 Hospital-acquired infections therapeutics market driver impact
- Fig. 15 Hospital-acquired infections therapeutics market restraint impact
- Fig. 16 Hospital-acquired infections therapeutics industry challenges
- Fig. 17 Porter's Five Forces Analysis
- Fig. 18 SWOT Analysis, By Factor (Political & legal Economic and technological)
- Fig. 19 Strategic alliance analysis
- Fig. 20 Recent developments & impact analysis, by key market participants
- Fig. 21 Key company market share analysis, 2019
- Fig. 22 Company market position analysis
- Fig. 23 Definition and scope, by drug class
- Fig. 24 Drug class market share analysis, 2019 & 2027
- Fig. 25 Segment dashboard
- Fig. 26 Global hospital-acquired infections therapeutics market, by drug class, 2016-2027 (USD Million)
- Fig. 27 Antibacterial drugs market size & forecasts and trend analysis, 2016 to 2027 (USD Million)
- Fig. 28 Cell wall synthesis inhibitors market size & forecasts and trend analysis, 2016 to 2027 (USD Million)
- Fig. 29 Protein synthesis inhibitors market size & forecasts and trend analysis, 2016 to 2027 (USD Million)
- Fig. 30 Other antibacterial drugs market size & forecasts and trend analysis, 2016 to 2027 (USD Million)

Fig. 31 Antiviral drugs market size & forecasts and trend analysis, 2016 to 2027 (USD Million)

Fig. 32 Antifungal drugs market size & forecasts and trend analysis, 2016 to 2027 (USD Million)

Fig. 33 Definition and scope, by infection type

Fig. 34 Infection type market share analysis, 2019 & 2027

Fig. 35 Segment dashboard

Fig. 36 Global hospital-acquired infections therapeutics market, by infection type, 2016-2027 (USD Million)

Fig. 37 Urinary tract infections market size & forecasts and trend analysis, 2016 to 2027 (USD Million)

Fig. 38 Ventilator-associated pneumonia market size & forecasts and trend analysis, 2016 to 2027 (USD Million)

Fig. 39 Surgical site infections market size & forecasts and trend analysis, 2016 to 2027 (USD Million)

Fig. 40 Bloodstream infections market size & forecasts and trend analysis, 2016 to 2027 (USD Million)

Fig. 41 Others market size & forecasts and trend analysis, 2016 to 2027 (USD Million)

Fig. 42 Hospital-acquired infections therapeutics market: Snapshot, 2019

Fig. 43 North America hospital-acquired infections therapeutics market share and leading players, 2019

Fig. 44 Europe hospital-acquired infections therapeutics market share and leading players, 2019

Fig. 45 Asia Pacific hospital-acquired infections therapeutics market share and leading players, 2019

Fig. 46 Latin America hospital-acquired infections therapeutics market share and leading players, 2019

Fig. 47 Middle East and Africa hospital-acquired infections therapeutics market share and leading players, 2019

Fig. 48 North America market share analysis by country, 2019

Fig. 49 Europe market share analysis by country, 2019

Fig. 50 Asia Pacific market share analysis by country, 2019

Fig. 51 Latin America market share analysis by country, 2019

Fig. 52 Middle East and Africa market share analysis by country, 2019

Fig. 53 North America SWOT analysis, by factor (political & legal, economic and technological)

Fig. 54 Europe SWOT analysis, by factor (political & legal, economic and technological)

Fig. 55 Asia Pacific SWOT analysis, by factor (political & legal, economic and technological)

Fig. 56 Latin America SWOT analysis, by factor (political & legal, economic and technological)

Fig. 57 Middle East and Africa SWOT analysis, by factor (political & legal, economic and technological)

Fig. 58 North America market size, & forecasts and trend analysis, 2016 to 2027 (USD Million)

Fig. 59 U.S. market size, & forecasts and trend analysis, 2016 to 2027 (USD Million)

Fig. 60 Canada market size, & forecasts and trend analysis, 2016 to 2027 (USD Million)

Fig. 61 Europe market size, & forecasts and trend analysis, 2016 to 2027 (USD Million)

Fig. 62 U.K. market size, & forecasts and trend analysis, 2016 to 2027 (USD Million)

Fig. 63 Germany market size, & forecasts and trend analysis, 2016 to 2027 (USD Million)

Fig. 64 Spain market size, & forecasts and trend analysis, 2016 to 2027 (USD Million)

Fig. 65 France market size, & forecasts and trend analysis, 2016 to 2027 (USD Million)

Fig. 66 Italy market size, & forecasts and trend analysis, 2016 to 2027 (USD Million)

Fig. 67 Russia market size, & forecasts and trend analysis, 2016 to 2027 (USD Million)

Fig. 68 Asia Pacific market size, & forecasts and trend analysis, 2016 to 2027 (USD Million)

Fig. 69 China market size, & forecasts and trend analysis, 2016 to 2027 (USD Million)

Fig. 70 Japan market size, & forecasts and trend analysis, 2016 to 2027 (USD Million)

Fig. 71 India market size, & forecasts and trend analysis, 2016 to 2027 (USD Million)

Fig. 72 Australia market size, & forecasts and trend analysis, 2016 to 2027 (USD Million)

Fig. 73 South Korea market size, & forecasts and trend analysis, 2016 to 2027 (USD Million)

Fig. 74 Singapore market size, & forecasts and trend analysis, 2016 to 2027 (USD Million)

Fig. 75 Latin America market size, & forecasts and trend analysis, 2016 to 2027 (USD Million)

Fig. 76 Brazil market size, & forecasts and trend analysis, 2016 to 2027 (USD Million)

Fig. 77 Mexico market size, & forecasts and trend analysis, 2016 to 2027 (USD Million)

Fig. 78 Argentina market size, & forecasts and trend analysis, 2016 to 2027 (USD Million))

Fig. 79 Middle East and Africa market size, & forecasts and trend analysis, 2016 to 2027 (USD Million)

Fig. 80 South Africa market size, & forecasts and trend analysis, 2016 to 2027 (USD Million)

Fig. 81 Saudi Arabia market size, & forecasts and trend analysis, 2016 to 2027 (USD Million)

Fig. 82 UAE market size, & forecasts and trend analysis, 2016 to 2027 (USD Million)

I would like to order

Product name: Hospital Acquired Infections Therapeutic Market Size, Share & Trends Analysis Report By Drug Class (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs), By Infection Type, By Region, And Segment Forecasts, 2020 - 2027

Product link: <https://marketpublishers.com/r/HD1A623FBA68EN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HD1A623FBA68EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970